作者：任园园，程功，冯盼盼，张骥，贾硕，李兆，蒋红英，王依阳

单位：

1.710068陕西省西安市，西安医学院 2.710068陕西省西安市，陕西省人民医院心内科 3.710068陕西省西安市，陕西省人民医院全科医学 4.710068陕西省西安市，陕西省人民医院急诊科 通信作者：程功，E-mail：xachenggong@163.com

单位（英文）：

1.Xi'an Medical College, Xi'an 710068, China 2.Department of Cardiology, Shaanxi Provincial People's Hospital, Xi'an 710068, China 3.General Medicine, Shaanxi Provincial People's Hospital, Xi'an 710068, China 4.Department of Emergency, Shaanxi Provincial People's Hospital, Xi'an 710068, China Corresponding author: CHENG Gong, E-mail: xachenggong@163.com

关键词：

血脂异常; 心血管疾病; PCSK9抑制剂; 鱼油制剂; 新型生物靶向降脂药物; 综述;

关键词（英文）：

Dyslipidemia; Cardiovascular diseases; PCSK9 inhibitors; Fish oil preparations; New biological targetedlipid-lowering drugs; Review

中图分类号：

DOI：

10.12114/j.issn.1008-5971.2022.00.099

基金项目：

陕西省中医药科研项目（2021-ZZ-ZY003）

摘要：

血脂异常在动脉粥样硬化发生、发展过程中起重要作用,是动脉粥样硬化性心血管疾病的最主要危险因素之一。目前研究表明,尽管经他汀类药物治疗后低密度脂蛋白胆固醇(LDL-C)降至指南推荐水平,但仍有40%的患者存在残余心血管风险。近年降脂治疗的研究进展迅速,新靶点、新型药物的研发或可进一步降低患者的残余心血管风险。本文结合国内外多项大型临床研究及《2021 ESC心血管疾病预防指南》,对前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂、鱼油制剂及新型生物靶向降脂药物最新研究进展进行综述,并探讨LDL-C目标值过低的安全性、特殊人群降脂治疗及脂蛋白a〔Lp(a)〕能否成为降脂治疗新靶点。

英文摘要：

【Abstract】 Dyslipidemia plays an important role in the occurrence and development of atherosclerosis, and is one of themost important risk factors of atherosclerotic cardiovascular diseases. Current research shows that although low density lipoproteincholesterol (LDL-C) drops to the recommended level after statins treatment, 40% of patients still have residual cardiovascularrisks. In recent years, the research on lipid-lowering therapy has made rapid progress, and the development of new targets andnew drugs may further reduce the residual cardiovascular risks of patients. Combined with many large-scale clinical studies athome and abroad and the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice, this paper reviews thelatest research progress of pre-protein converting enzyme subtilisin 9 (PCSK9) inhibitors, fish oil preparations and new biologicaltargeted lipid-lowering drugs, and discusses the safety of low LDL-C target value, lipid-lowering therapy for special populationand whether lipoprotein a [Lp (a) ] can be a new target for lipid-lowering therapy.

参考文献：